Envafolimab + Regorafenib
NCT06772233
Peking University · Phase 2 · Not yet recruiting · Enrollment 100
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|
No efficacy figure is in this file for this study.
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
Envafolimab + Regorafenib
Peking University · Phase 2 · Not yet recruiting · Enrollment 100
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|
No efficacy figure is in this file for this study.